Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion type Assertion NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_head.
- NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion description "[Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_provenance.
- NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion evidence source_evidence_literature NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_provenance.
- NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion SIO_000772 16287063 NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_provenance.
- NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion wasDerivedFrom befree-20150227 NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_provenance.
- NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_assertion wasGeneratedBy ECO_0000203 NP608639.RAc1nStpA56RQXVM19jKLjth_QxuGOgi7jIEUN6FOBVW4130_provenance.